Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EMA Emera Inc.

交易中 10-09 11:55:29 EDT

45.47

-0.38

-0.83%

最高45.73	最低45.27	成交量16.63万
今开45.61	昨收45.85	日振幅1.00%
总市值139.04亿	流通市值139.04亿	总股本3.06亿
成交额755.97万	换手率0.05%	流通股本3.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":45.47,"timestamp":1791561323473,"preClose":45.85,"halted":0,"volume":166317,"delay":0,"changeRate":-0.00828789531079613,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"交易中","change":-0.38,"latestTime":"10-09 11:55:29 EDT","open":45.61,"high":45.73,"low":45.27,"amount":7559718.03339,"amplitude":0.010033,"askPrice":45.48,"askSize":1000,"bidPrice":45.45,"bidSize":228,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":45.85,"dividendRate":0.045276,"postHourTrading":{"tag":"盘后","latestPrice":45.85,"preClose":45.85,"latestTime":"19:30 EDT","volume":1119037,"amount":51326168.544014,"timestamp":1791502204763,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.328759,"impliedVol":0.3225,"impliedVolPercentile":0.8526},"requestUrl":"/m/hq/s/EMA/tweets","defaultTab":"tweets","newsList":[{"id":"2673705541","title":"Emera（EMA）与Canadian Utilities合并 跻身北美前20公用事业企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705541","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673705541?lang=zh_cn&edition=full","pubTime":"2026-10-06 19:31","pubTimestamp":1791286303,"startTime":"0","endTime":"0","summary":"按Canadian Utilities的隐含企业价值测算，该交易将成为加拿大本土企业之间规模最大的一笔合并，新公司也将跻身北美前20大公用事业企业。根据交易条款，Emera将收购Canadian Utilities及ATCO全部已发行流通股份；ATCO旗下工业服务业务将分拆为New ATCO。股权分配方面，Emera股东将持有合并后实体约60%股份，Canadian Utilities股东持股约40%。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MWZlOWI0Y2VlNGE3Yjk5M2Y5NzBkYzExODBlYTA4MTI1NDQ2NzI2NDIw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MWZlOWI0Y2VlNGE3Yjk5M2Y5NzBkYzExODBlYTA4MTI1NDQ2NzI2NDIw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306877","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","REGL","NOBL","BK4588","PY","159301","BILD","EMA","BK4081","IGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669135286","title":"“减肥神药”司美格鲁肽制造商遭患者起诉 罕见眼病风险争议升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2669135286","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669135286?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:12","pubTimestamp":1789953162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668183959","title":"数十名患者起诉司美格鲁肽制造商","url":"https://stock-news.laohu8.com/highlight/detail?id=2668183959","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668183959?lang=zh_cn&edition=full","pubTime":"2026-09-20 15:28","pubTimestamp":1789889280,"startTime":"0","endTime":"0","summary":"近日，美国数十人因在服药期间患上眼疾而起诉司美格鲁肽的制造商诺和诺德。这名患者在就医时表示，服用司美格鲁肽治疗2型糖尿病长达6个月，医生要求其立即停药，以保护剩余的视力。自2025年以来，处理人身伤害案的律师事务所魏茨与卢森伯格律师事务所代表芬内尔在内的患者，在新泽西州州法院提起了90多起诉讼，这些患者在服用司美格鲁肽期间患上NAION，正在向诺和诺德索赔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-20/doc-inisnhca6675853.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-20/doc-inisnhca6675853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AOA","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662639772","title":"伯维（ABBV）向EMA递交Skyrizi克罗恩病治疗上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639772","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662639772?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:56","pubTimestamp":1787821007,"startTime":"0","endTime":"0","summary":"Skyrizi此前已经在银屑病、银屑病关节炎等多个自身免疫疾病领域拿到欧洲地区的获批资质，如若本次克罗恩病适应症顺利获批，将进一步拓宽该产品在欧洲炎症性肠病赛道的市场空间。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","GLAM","LU1236620750.USD","SG9999011175.SGD","LU1839511570.USD","LU1236620834.HKD","LU0289739699.SGD","LU0661504455.SGD","LU0128525929.USD","LU2087621335.USD","LU1267930573.SGD","LU0114720955.EUR","LU0965508806.USD","VHT","IE000F7OJYX1.SGD","LU0472753341.HKD","FHLC","IPOS","LU1585245621.USD","LU1989771016.USD","LU2023251221.USD","LU0417517546.SGD","PJP","LU2125909247.SGD","LU2237443622.USD","LU0234572021.USD","TRUH","FTXH","LU2125909593.SGD","BK4533","ABBV","XLV","LU0882574055.USD","PPH","MEDX","JDOC","LU0198837287.USD","LU2133065610.SGD","LU0985320562.USD","IYH","LU0058720904.USD","LU1732799900.SGD","IE00BLSP4239.USD","LU2089283258.USD","IXJ","SG9999001440.SGD","EMA","IE0004445239.USD","RXL","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200130","title":"中化国际EMA项目投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200130?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:09","pubTimestamp":1787623784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera（EMA）上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657648031?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度，Emera实现调整后净利润2.12亿加元，较上年同期的2.36亿加元有所放缓；净利润为1.05亿加元。2026年上半年，公司调整后净利润达到6.27亿加元，高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元，低于去年同期的7.18亿加元。展望未来，公司预计，2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位，公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148281703?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报，市场预期营收增长而利润承压，投资者关注盈利质量与现金流稳定性。一致预期显示，本季度Emera Inc.营收为20.29亿加元，同比增长15.89%；调整后每股收益为0.49加元，同比下降24.17%；EBIT为4.73亿加元，同比增长1.23%，上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元，同比增长5.12%；毛利率50.20%；归属于母公司股东的净利润5.82亿加元，净利率20.69%；调整后每股收益同比增长7.00%，净利润环比增长568.97%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B：核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654001188?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EMA","BMED","BK4081","MDTX","PSYK","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股价站稳200日EMA上方：获NASA合同后是否值得买入？","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647037238?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨，此前该公司宣布将收购卫星通信运营商Iridium，交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同，为股价提供了技术面支撑。　　从技术走势来看，Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑，目前盘前交易于90美元附近，成功站稳200日指数移动平均线上方。　　上周，NASA宣布选择Rocket Lab执行三项Electron火箭发射任务，用于PolSIR和TSIS-2科学任务，预计于2027年初启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0217","BK4081","EMA","300785","NASA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞医药(600276.SH)：瑞维鲁胺片上市许可申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645409710?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到了欧洲药品管理局(European Medicines Agency，简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请，这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT)，治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","LU1820825898.SGD","01276","LU2289578879.USD","LU2495084118.USD","BK0196","LU1064131003.USD","IPOS","LU1146622755.USD","LU2488822045.USD","LU1969619763.USD","LU0405327494.USD","LU1997244956.HKD","LU0405327148.USD","LU1655091616.SGD","BK0188","600276","LU1997245094.SGD","LU0359201612.USD","LU2328871848.SGD","LU1328615791.USD","BK1191","LU2543165471.USD","LU2580892789.USD","LU1997245177.USD","BK0183","LU1255011170.USD","LU1781817850.SGD","LU2097828557.USD","BK0012","LU2097828474.EUR","LU2097828805.USD","BK0028","LU2148510915.USD","LU0359201885.HKD","BK0239","LU1580142542.USD","LU2097828631.EUR","EMA","LU1023057109.AUD","BK4081","LU0359202008.SGD","BK0060","LU2097828714.EUR","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185761853?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩，市场关注营收增速与成本控制的落地情况。根据一致预期，本季度Emera Inc.营收预计为30.09亿加元，同比增长35.49%；调整后每股收益预计为1.15加元，同比增长15.55%；息税前利润预计为7.02亿加元，同比增长7.05%；当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"罗氏获欧洲监管机构反馈后，启动Elevidys基因疗法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627213629?lang=zh_cn&edition=full","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症，由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前，因两例患者死亡事件与该疗法相关而引发审查，这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩，其中包括美国。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0967},{"period":"3month","weight":-0.1406},{"period":"6month","weight":-0.1415},{"period":"1year","weight":-0.0454},{"period":"ytd","weight":-0.0688}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Inc.于1998年7月23日在加拿大注册成立，是一家北美能源服务提供商，拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州，并在加拿大大西洋省、新墨西哥州和加勒比地区增加了业务。Emera总部位于新斯科舍省哈利法克斯，其业务战略侧重于对其受监管的公用事业、卓越运营和效率进行持续投资，以便为其270万客户可靠地提供能源。公司在受监管公用事业的盈利机会取决于净投资规模、资本结构权益和目标回报，这些都是通过监管建立起来的。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}